Lenox-Smith, Alan
Reed, Catherine
Lebrec, Jeremie
Belger, Mark
Jones, Roy W.
Funding for this research was provided by:
Eli Lilly and Company (N/A)
Article History
Received: 7 June 2017
Accepted: 15 February 2018
First Online: 23 February 2018
Ethics approval and consent to participate
: Ethical review board approval of the study was obtained according to UK regulations and written informed consent was obtained from all participants or their caregivers. Each site determined whether proxy consent was required for participants or whether they were able to provide their own consent.National ethics committee approvals obtained: UK: NHS National Research Ethics Service, South West 5 REC (reference [CitationRef removed]/H0107/43); Scotland A Research Ethics Committee (reference number 10/MRE00/63).
: Not applicable.
: ALS is a full-time employee and shareholder of Eli Lilly.CCR is a full-time employee and shareholder of Eli Lilly.JL works as a full-time contractor for Eli Lilly.MB is a full-time employee and shareholder of Eli Lilly.RWJ has received honoraria and consultancy fees from Eli Lilly and other companies involved in research to find new treatments for AD; his institution received research funding for participation in the GERAS study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.